Benzinga's Small Cap Movers for Wednesday December 19, 2012
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of Dynatronics (NASDAQ: DYNT), the Salt Lake City, designer, manufacturer, distributor and marketer of physical medicine and aesthetic products, rose 46% Wednesday on 23 times average volume.
Dynatronics announced Wednesday that on December 17, 2012, at the Company's annual meeting, the shareholders approved a one-for-five reverse stock split of the Company's common stock.
Approximately 93% of the votes cast were in favor of the reverse split which becomes effective Wednesday.
Dynatronics closed at $3.07 on Wednesday.
Better Online Solutions
Shares of Better Online Solutions (NASDAQ: BOSC), the Israel-based the Israel-based provider of RFID and Supply Chain solutions to global enterprises, rose 73% Wednesday on 43 times average volume.
There was no news on Wednesday to account for the move.
Better Online Solutions closed at $8.19 on Wednesday.
Shares of Idera Pharmaceuticals (NASDAQ: IDRA), the Cambridge, MA biotechnology company, rose 19% Wednesday on 34 times average volume.
Idera Pharmaceuticals announced Wednesday that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period. None of the 12 placebo-treated patients had improvement in this range; this difference was statistically significant (p<0.005). The Company believes the results of this trial provide clinical proof-of-concept for the mechanism of action of selective TLR inhibition in patients with psoriasis and potentially other autoimmune and inflammatory disorders.
Idera Pharmaceuticals closed at $0.92 on Wednesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.